Company / Free Cash Flow
Insight Molecular Diagnostics Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$21.2M
FY2025
5-year range
-$49.9M / -$21.2M
FY2021-FY2025
Trend
+10.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$50M to -$21M over the past 2 years.
Based on SEC 10-K filings.
-$21M in FY2025.
Improved from -$50M to -$21M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 10.2% year-over-year.
- Peak free cash flow was recorded in FY2020.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$21.2M | +10.2% |
| FY2024 | -$23.6M | +52.7% |
| FY2023 | -$49.9M | -30.7% |
| FY2022 | -$38.2M | -40.4% |
| FY2021 | -$27.2M | -31.9% |
| FY2020 | -$20.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026